JP7595593B2 - 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物 - Google Patents

増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物 Download PDF

Info

Publication number
JP7595593B2
JP7595593B2 JP2021571989A JP2021571989A JP7595593B2 JP 7595593 B2 JP7595593 B2 JP 7595593B2 JP 2021571989 A JP2021571989 A JP 2021571989A JP 2021571989 A JP2021571989 A JP 2021571989A JP 7595593 B2 JP7595593 B2 JP 7595593B2
Authority
JP
Japan
Prior art keywords
formula
compound
pyrimidin
ethoxypyrazin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536092A (ja
JP2022536092A5 (cg-RX-API-DMAC7.html
Inventor
クドドス アブドル
ノバク アンドリュー
カズン デービッド
ブラックハム エマ
ジョーンズ ゲラント
ウリグルワース ジョセフ
ダフィー ローナ
バーチ ルイーズ
ジョージ パスカル
アーメド サレフ
Original Assignee
ステップ ファーマ エス．エー．エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステップ ファーマ エス．エー．エス filed Critical ステップ ファーマ エス．エー．エス
Publication of JP2022536092A publication Critical patent/JP2022536092A/ja
Publication of JP2022536092A5 publication Critical patent/JP2022536092A5/ja
Application granted granted Critical
Publication of JP7595593B2 publication Critical patent/JP7595593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021571989A 2019-06-04 2020-06-04 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物 Active JP7595593B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19305713 2019-06-04
EP19305713.0 2019-06-04
EP19306144.7 2019-09-20
EP19306144 2019-09-20
PCT/IB2020/000559 WO2020245664A1 (en) 2019-06-04 2020-06-04 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
JP2022536092A JP2022536092A (ja) 2022-08-12
JP2022536092A5 JP2022536092A5 (cg-RX-API-DMAC7.html) 2023-06-23
JP7595593B2 true JP7595593B2 (ja) 2024-12-06

Family

ID=71895028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571989A Active JP7595593B2 (ja) 2019-06-04 2020-06-04 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物

Country Status (10)

Country Link
US (1) US12466810B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980411B1 (cg-RX-API-DMAC7.html)
JP (1) JP7595593B2 (cg-RX-API-DMAC7.html)
CN (1) CN114008039B (cg-RX-API-DMAC7.html)
DK (1) DK3980411T3 (cg-RX-API-DMAC7.html)
ES (1) ES3044436T3 (cg-RX-API-DMAC7.html)
FI (1) FI3980411T3 (cg-RX-API-DMAC7.html)
HU (1) HUE073329T2 (cg-RX-API-DMAC7.html)
IL (1) IL288508B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020245664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717465B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
US20240425473A2 (en) * 2021-02-01 2024-12-26 University Of Southern California Enzyme inhibitors and viral infection therapy
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
WO2023166076A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combinations of ctps1 and bcl2 inhibitors for cancer
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
CN118359588A (zh) * 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物
WO2026027753A1 (en) * 2024-08-02 2026-02-05 Step Pharma S.A.S. Ctps1 inhibitors for the treatment of myeloproliferative neoplasms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523818A (ja) 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるｔ細胞増殖を阻害するための方法及び医薬組成物（ｃｔｐｓ１阻害剤、例えばノルロイシン）

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417507A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
US7091201B2 (en) * 2000-09-25 2006-08-15 Actelion Pharmaceuticals Ltd. Arylalkane-sulfonamides having endothelin-antagonist activity
US20030158218A1 (en) 2001-12-21 2003-08-21 Nantermet Philippe G. Thrombin inhibitors
US8008302B2 (en) 2004-07-26 2011-08-30 Merck Serono Sa N-hydroxyamide derivatives and use thereof
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
AU2008335709A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
KR101097312B1 (ko) 2009-08-10 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2601185B1 (en) * 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
MX2013005567A (es) * 2010-11-17 2013-10-30 Amgen Inc Derivados de quinolina como inhibidores de pik3.
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
JP2016028795A (ja) 2013-03-28 2016-03-03 国立研究開発法人科学技術振興機構 触媒金属ナノ粒子含有複合体及びその利用
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
GB201322333D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res WNT pathway modulators
KR102525131B1 (ko) 2014-10-08 2023-04-24 레드엑스 파마 피엘씨 Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체
CN104262071A (zh) 2014-10-16 2015-01-07 中国科学院山西煤炭化学研究所 一种联苯类化合物的光催化合成方法
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3492454A1 (en) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
EP3717465B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
MX2020009887A (es) * 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
US20230192673A1 (en) 2018-06-04 2023-06-22 Step Pharma S.A.S. Compounds
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
EP3980410B1 (en) 2019-06-04 2025-02-19 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP4041715A1 (en) 2019-09-20 2022-08-17 Step Pharma S.A.S. Sulfonamide inhibitors as ctps 1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166076A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combinations of ctps1 and bcl2 inhibitors for cancer
WO2023205475A1 (en) 2022-04-21 2023-10-26 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
CN118359588A (zh) 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523818A (ja) 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるｔ細胞増殖を阻害するための方法及び医薬組成物（ｃｔｐｓ１阻害剤、例えばノルロイシン）

Also Published As

Publication number Publication date
WO2020245664A1 (en) 2020-12-10
CN114008039A (zh) 2022-02-01
IL288508A (en) 2022-01-01
EP3980411A1 (en) 2022-04-13
FI3980411T3 (fi) 2025-10-28
US12466810B2 (en) 2025-11-11
JP2022536092A (ja) 2022-08-12
IL288508B1 (en) 2025-10-01
US20220324837A1 (en) 2022-10-13
CN114008039B (zh) 2024-01-16
EP3980411B1 (en) 2025-07-23
ES3044436T3 (en) 2025-11-26
DK3980411T3 (da) 2025-10-13
IL288508B2 (en) 2026-02-01
HUE073329T2 (hu) 2026-01-28

Similar Documents

Publication Publication Date Title
JP7595593B2 (ja) 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物
US12371419B2 (en) Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors
JP7667225B2 (ja) Ｃｔｐｓ１阻害剤としてのアミノピリミジン誘導体
US12319680B2 (en) Compounds
WO2021053403A1 (en) Sulfonamide inhibitors as ctps1 inhibitors
WO2021053402A2 (en) Compounds
HK40073180B (en) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases
HK40073180A (en) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases
HK40059463A (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
HK40059463B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
EA050418B1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241126

R150 Certificate of patent or registration of utility model

Ref document number: 7595593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150